Qube Research & Technologies LTD Mi Nk Therapeutics, Inc. Transaction History
Qube Research & Technologies LTD
- $62.3 Billion
- Q2 2024
A detailed history of Qube Research & Technologies LTD transactions in Mi Nk Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 1,941 shares of INKT stock, worth $1,436. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,941
Previous 1,941
-0.0%
Holding current value
$1,436
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding INKT
# of Institutions
34Shares Held
901KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA234KShares$173,2940.0% of portfolio
-
Longbow Finance Sa Lutry, V8167KShares$123,3320.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny128KShares$94,6020.0% of portfolio
-
Geode Capital Management, LLC Boston, MA96.3KShares$71,2960.0% of portfolio
-
Black Rock Inc. New York, NY87.2KShares$64,5250.0% of portfolio
About MiNK Therapeutics, Inc.
- Ticker INKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,775,100
- Market Cap $25M
- Description
- MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...